Chronic myelogenous leukemia in accelerated phase.
Huang
Qin
Q
Division of Pathology, City of Hope National Medical Center, Duarte, Calif 91010, USA. qhuang@coh.org
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D001549:Benzamides; D002886:Chromosomes, Human, Pair 17; D002889:Chromosomes, Human, Pair 2; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D017809:Fatal Outcome; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D010087:Oxides / Q000008:administration & dosage; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D014178:Translocation, Genetic
D001152:Arsenicals; D001549:Benzamides; D010087:Oxides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000077237:Arsenic Trioxide; D006918:Hydroxyurea